Clinical Trial News and Research

RSS

GEMINI LTS study: Patients with active ulcerative colitis report clinical improvements with vedolizumab treatment

Takeda Pharmaceutical Company Limited, (“Takeda”) today announced that the interim findings from the GEMINI Long-Term Safety (LTS) study were presented during the 2016 European Crohn's and Colitis Organisation (ECCO) Annual Scientific Meeting in Amsterdam, The Netherlands.

22 Mar 2016

Metabolite in gut microbiome could improve outcomes after bone marrow transplant

Could playing better defense make bone marrow transplants more successful? With this question in mind, researchers began looking at whether the trillions of little bugs and bacteria living in our gastrointestinal tract could be the key to playing defense.

22 Mar 2016

Stress management can cut risk of another heart attack by half

Patients recovering from heart attacks or other heart trouble could cut their risk of another heart incident by half if they incorporate stress management into their treatment, according to research from Duke Health.

22 Mar 2016

LEO Pharma announces scientific approval of Enstilar for treatment of people living with psoriasis in EU

LEO Pharma today announced that it received scientific approval of Enstilar (calcipotriol/betamethasone dipropionate 50 micrograms/g / 0,5 mg/g) for the treatment of psoriasis vulgaris in patients 18 years of age or older.

21 Mar 2016

Study assesses acceptability of alternative drug to prevent malaria among pregnant women in Kenya

Researchers at LSTM, working with colleagues at the Centres for Disease Control and Prevention USA, the Kenya Medical Research Institute, and from the London School of Hygiene and Tropical Medicine, have completed a study to assess the acceptability among pregnant women and health providers in Kenya of a new drug as an alternative to the standard drug used to prevent malaria in pregnancy.

21 Mar 2016

Novel compound shows promise as potential treatment for acute myeloid leukemia

A novel compound has shown promise in preclinical studies as a treatment for acute myeloid leukemia, more than doubling median days of survival even in a drug-resistant form of the disease.

21 Mar 2016

Simple TB screening and isoniazid can be effective for HIV patients at risk for TB

The number one killer of HIV patients in resource-limited areas, including parts of Africa and India, is tuberculosis (TB), underscoring the need for optimal treatments and effective strategies to address this deadly co-infection. But TB is harder to detect in HIV-infected patients and diagnostic test results take time, so many healthcare providers prescribe multi-drug TB treatments as a precaution.

20 Mar 2016

Neutralizing acidic tumor environment increases efficacy of immune-targeting cancer therapies

Cancer cells have the ability to grow in an acidic tumor environment that is detrimental to other cells, including immune cells. In a Cancer Research cover article published this week, Moffitt Cancer Center reported that neutralizing the acidic tumor environment increases the efficacy of several immune-targeting cancer therapies.

19 Mar 2016

Findings could be final puzzle piece in developing effective dengue vaccine

In a small clinical trial led by the Johns Hopkins Bloomberg School of Public Health, researchers say that a promising single-dose dengue vaccine, developed by scientists at the National Institutes of Health, was 100 percent effective in preventing human volunteers from contracting the virus, the most prevalent mosquito-borne virus in the world.

18 Mar 2016

Genomic profiling could help provide targeted therapies for difficult to treat cancer tumors

Research from Rutgers Cancer Institute of New Jersey examining difficult to treat cancer tumors through genomic profiling shows that tumors with alterations in a signaling pathway responsible for cell regulation may respond to targeted therapy regardless of where the tumor originated in the body.

18 Mar 2016

Clinical study finds no added benefit of using four TB drugs to save people with advanced HIV/AIDS

In a report on the so-called REMEMBER (Reducing Early Mortality and Early Morbidity by Empiric Tuberculosis Treatment) study -- a 10-nation, randomized clinical trial of adult outpatients -- investigators concluded that there was no added benefit of using four drugs for TB over just using one drug, isoniazid, to save lives in people with advanced HIV/AIDS.

18 Mar 2016

Real-life data show feasibility of imatinib discontinuation in CML

Italian research shows that long-term imatinib discontinuation is feasible outside of a clinical trial setting for patients with chronic myeloid leukaemia who achieve stable undetectable molecular disease with front-line treatment.

17 Mar 2016

Psoriasis patients experience widespread bone loss

Researchers from the Genes, Development and Disease Group, headed by Erwin Wagner at the Spanish National Cancer Research Centre have discovered that psoriasis patients experience a widespread bone loss as a result of the disease.

17 Mar 2016

Halozyme Therapeutics doses first patient in Halo-301 | Pancreatic study

Halozyme Therapeutics, Inc., a biotechnology company developing novel oncology and drug-delivery therapies, today announced the first patient has been dosed in its Halo-301 | Pancreatic study, a Phase 3 clinical trial in previously untreated metastatic pancreatic cancer patients.

16 Mar 2016

New treatment reduces cerebral damage in out-of-hospital cardiac arrest patients

Among comatose survivors of out-of-hospital cardiac arrest, treatment with inhaled xenon gas combined with hypothermia, compared with hypothermia alone, results in less white matter damage.

16 Mar 2016

Anti-anxiety drug reduces autistic features in Jacobsen syndrome mice

About half of children born with Jacobsen syndrome, a rare inherited disease, experience social and behavioral issues consistent with autism spectrum disorders. Researchers at University of California, San Diego School of Medicine and collaborators developed a mouse model of the disease that also exhibits autism-like social behaviors and used it to unravel the molecular mechanism that connects the genetic defects inherited in Jacobsen syndrome to effects on brain function.

16 Mar 2016

New method to harvest stem cells reduces side effects for donors

Australian scientists have developed a new method for harvesting stem cells, which is less invasive and reduces side effects for donors.

16 Mar 2016

Experimental drug improves survival rate of majority of lung cancer patients compared to standard chemotherapy

In global clinical trials, patients with advanced metastatic lung cancer who were treated with a targeted immunotherapy drug lived significantly longer and with fewer side effects than those who received standard second-line chemotherapy, according to a new Kaiser Permanente study published today in the journal The Lancet.

15 Mar 2016

DelMar's VAL-083 receives FDA orphan drug designation for treatment of medulloblastoma

DelMar Pharmaceuticals, Inc., announced today that the FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation for its lead product candidate, VAL-083, in the treatment of medulloblastoma.

15 Mar 2016

Orexigen Therapeutics, Valeant Pharmaceuticals sign distribution agreement for Mysimba

Orexigen Therapeutics, Inc. today announced Valeant Pharmaceuticals International, Inc. will commercialize Mysimba (naltrexone HCl / bupropion HCl prolonged release) in Central and Eastern Europe.

15 Mar 2016

Clinical Trial News and Research

GEMINI LTS study: Patients with active ulcerative colitis report clinical improvements with vedolizumab treatment

Metabolite in gut microbiome could improve outcomes after bone marrow transplant

Stress management can cut risk of another heart attack by half

LEO Pharma announces scientific approval of Enstilar for treatment of people living with psoriasis in EU

Study assesses acceptability of alternative drug to prevent malaria among pregnant women in Kenya

Novel compound shows promise as potential treatment for acute myeloid leukemia

Simple TB screening and isoniazid can be effective for HIV patients at risk for TB

Neutralizing acidic tumor environment increases efficacy of immune-targeting cancer therapies

Findings could be final puzzle piece in developing effective dengue vaccine

Genomic profiling could help provide targeted therapies for difficult to treat cancer tumors

Clinical study finds no added benefit of using four TB drugs to save people with advanced HIV/AIDS

Real-life data show feasibility of imatinib discontinuation in CML

Psoriasis patients experience widespread bone loss

Halozyme Therapeutics doses first patient in Halo-301 | Pancreatic study

New treatment reduces cerebral damage in out-of-hospital cardiac arrest patients

Anti-anxiety drug reduces autistic features in Jacobsen syndrome mice

New method to harvest stem cells reduces side effects for donors

Experimental drug improves survival rate of majority of lung cancer patients compared to standard chemotherapy

DelMar's VAL-083 receives FDA orphan drug designation for treatment of medulloblastoma

Orexigen Therapeutics, Valeant Pharmaceuticals sign distribution agreement for Mysimba

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Event guide: 2nd World RNA-Based Therapeutics & Vaccines Summit Korea

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery